ASCLETIS-B (01672) surged over 6%, reaching HK$14.46 by the time of writing, with a trading volume of HK$39.59 million.

On November 13, Pfizer announced the successful acquisition of Metsera for approximately $9.2 billion, gaining key assets MET-097i and MET-233i. Meanwhile, Eli Lilly and Novo Nordisk have also been actively expanding their ultra-long-acting therapy platforms. In 2025, they entered strategic partnerships with Camurus and Ascendis, respectively, leveraging FluidCrystal and TransCon subcutaneous depot technologies to develop ultra-long-acting weight-loss and diabetes treatments.

According to research from Kaiyuan Securities, as more clinical data emerges, the value of ultra-long-acting pipelines and technology platforms will become increasingly evident. The firm predicts that ultra-long-acting therapies will become the most differentiated competitive direction in the weight-loss and diabetes treatment sector.

The report highlights that technologies such as antibody-drug conjugates, fatty acid modification, and subcutaneous depot-controlled release can enable ultra-long-acting drug delivery. Notably, ASCLETIS-B has already established its subcutaneous depot ULAP technology platform, using it to develop multiple ultra-long-acting weight-loss drug candidates.